Treatment of psoriasis

Role of calcipotriene

Robert Kirsner, D. Federman

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Psoriasis, a common skin disorder, affects over 1 percent of the population of the United States. The majority of these patients have limited disease that can be managed with topical therapy. Topical treatment includes corticosteroids, tar, anthralin and keratolytic agents. Calcipotriene, a new topical treatment for psoriasis of mild to moderate severity, is a vitamin D derivative that inhibits epidermal cell proliferation in vitro. Treatment with calcipotriene results in decreased redness, scaling and thickness of the plaque. Calcipotriene is comparable to mid-potency topical corticosteroids in efficacy, but it does not cause skin atrophy and apparently does not lead to tachyphylaxis. Irritant dermatitis is a common side effect of calcipotriene, especially when it is applied to the face. Careful patient monitoring is recommended because alterations in calcium metabolism have been reported to occur with use of calcipotriene.

Original languageEnglish
Pages (from-to)237-240
Number of pages4
JournalAmerican Family Physician
Volume52
Issue number1
StatePublished - Jan 1 1995

Fingerprint

Psoriasis
Keratolytic Agents
Adrenal Cortex Hormones
Anthralin
Irritant Dermatitis
Tachyphylaxis
Therapeutics
Tars
Skin
Physiologic Monitoring
Vitamin D
Atrophy
Cell Proliferation
calcipotriene
Calcium
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of psoriasis : Role of calcipotriene. / Kirsner, Robert; Federman, D.

In: American Family Physician, Vol. 52, No. 1, 01.01.1995, p. 237-240.

Research output: Contribution to journalArticle

Kirsner, R & Federman, D 1995, 'Treatment of psoriasis: Role of calcipotriene', American Family Physician, vol. 52, no. 1, pp. 237-240.
Kirsner, Robert ; Federman, D. / Treatment of psoriasis : Role of calcipotriene. In: American Family Physician. 1995 ; Vol. 52, No. 1. pp. 237-240.
@article{de9dd80b30e2437593d88054e07c0b5d,
title = "Treatment of psoriasis: Role of calcipotriene",
abstract = "Psoriasis, a common skin disorder, affects over 1 percent of the population of the United States. The majority of these patients have limited disease that can be managed with topical therapy. Topical treatment includes corticosteroids, tar, anthralin and keratolytic agents. Calcipotriene, a new topical treatment for psoriasis of mild to moderate severity, is a vitamin D derivative that inhibits epidermal cell proliferation in vitro. Treatment with calcipotriene results in decreased redness, scaling and thickness of the plaque. Calcipotriene is comparable to mid-potency topical corticosteroids in efficacy, but it does not cause skin atrophy and apparently does not lead to tachyphylaxis. Irritant dermatitis is a common side effect of calcipotriene, especially when it is applied to the face. Careful patient monitoring is recommended because alterations in calcium metabolism have been reported to occur with use of calcipotriene.",
author = "Robert Kirsner and D. Federman",
year = "1995",
month = "1",
day = "1",
language = "English",
volume = "52",
pages = "237--240",
journal = "American Family Physician",
issn = "0002-838X",
publisher = "American Academy of Family Physicians",
number = "1",

}

TY - JOUR

T1 - Treatment of psoriasis

T2 - Role of calcipotriene

AU - Kirsner, Robert

AU - Federman, D.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Psoriasis, a common skin disorder, affects over 1 percent of the population of the United States. The majority of these patients have limited disease that can be managed with topical therapy. Topical treatment includes corticosteroids, tar, anthralin and keratolytic agents. Calcipotriene, a new topical treatment for psoriasis of mild to moderate severity, is a vitamin D derivative that inhibits epidermal cell proliferation in vitro. Treatment with calcipotriene results in decreased redness, scaling and thickness of the plaque. Calcipotriene is comparable to mid-potency topical corticosteroids in efficacy, but it does not cause skin atrophy and apparently does not lead to tachyphylaxis. Irritant dermatitis is a common side effect of calcipotriene, especially when it is applied to the face. Careful patient monitoring is recommended because alterations in calcium metabolism have been reported to occur with use of calcipotriene.

AB - Psoriasis, a common skin disorder, affects over 1 percent of the population of the United States. The majority of these patients have limited disease that can be managed with topical therapy. Topical treatment includes corticosteroids, tar, anthralin and keratolytic agents. Calcipotriene, a new topical treatment for psoriasis of mild to moderate severity, is a vitamin D derivative that inhibits epidermal cell proliferation in vitro. Treatment with calcipotriene results in decreased redness, scaling and thickness of the plaque. Calcipotriene is comparable to mid-potency topical corticosteroids in efficacy, but it does not cause skin atrophy and apparently does not lead to tachyphylaxis. Irritant dermatitis is a common side effect of calcipotriene, especially when it is applied to the face. Careful patient monitoring is recommended because alterations in calcium metabolism have been reported to occur with use of calcipotriene.

UR - http://www.scopus.com/inward/record.url?scp=0028997113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028997113&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 237

EP - 240

JO - American Family Physician

JF - American Family Physician

SN - 0002-838X

IS - 1

ER -